Zacks Investment Research upgraded shares of Reneuron Gp (OTCMKTS:RNUGF) from a hold rating to a buy rating in a research note published on Friday morning.
According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “
Reneuron Gp (OTCMKTS:RNUGF) remained flat at $$0.02 during trading on Friday. Reneuron Gp has a 1-year low of $0.02 and a 1-year high of $0.05.
ILLEGAL ACTIVITY NOTICE: “Reneuron Gp (RNUGF) Upgraded to Buy by Zacks Investment Research” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/13/reneuron-gp-rnugf-upgraded-to-buy-by-zacks-investment-research.html.
Reneuron Gp Company Profile
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The companys lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.
Receive News & Ratings for Reneuron Gp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneuron Gp and related companies with MarketBeat.com's FREE daily email newsletter.